Medicaid

On Thursday, Senate Republicans unveiled their revised healthcare reform bill. Here’s everything you need to know. ‘Skinny’ Policies  The new bill allows insurers to sell “skinny” insurance plans that don’t meet the minimum coverage requirements currently in...

Analysts at Citi initiates coverage of Aetna Inc (NYSE: AET) with a Buy rating, $180 price target and named to the firm's "Citi Focus List." Aetna should be viewed as a "strong diversified health insurer" that is also well positioned to gain share within the government segment and has "stable...

A group of Republican senators, meeting secretly for weeks, finally unveiled on Thursday their version of a health care plan meant to replace the Affordable Care Act enacted by President Barack Obama. As expected, the 142-page bill — the American Heath Care Act — is similar to the...

Republicans in Congress promised to repeal the Affordable Care Act on the first day of a new GOP administration. Five months later, the overhaul remains stalled, just one part of an agenda paralyzed by the probe into President Donald Trump’s dealings with Russia. The U.S. Senate is working on...

It’s going to be busy this week in the healthcare industry, with several key developments on the schedule that could have a major impact on the U.S. healthcare sector. What A Week First, on Monday, the Centers for Medicare and Medicaid Services released the latest batch of Health Insurance...

It’s easy for the average American to dismiss the impact of the nation’s opioid abuse epidemic. However, heroin and prescription opioid painkiller addiction may be costing Americans much more than they realize. A recent study by the U.S. Surgeon General found that 27 million Americans...

The poor, the elderly, the disabled, college students and environmental protections all stand to take a big hit if Congress approves President Donald Trump’s $4.1 trillion budget for fiscal year 2018. Defense contractors, corporations in general and the wealthiest Americans all stand to gain...

Few investors consider a 150-year-old company as one that has a pathway toward growth, but there are always exceptions to every rule. Barclays' Joshua Raskin maintains an Overweight rating on the 150-year old diversified healthcare company Aetna Inc (NYSE: AET) with a $162 price target. In a...

Somewhere beyond the cacophony over President Donald Trump’s firing of FBI Director James Comey is a steady, behind-the-scenes hum about healthcare, which won’t stay yesterday’s news for very long. Analysts at Height Securities, LLC say the U.S. Senate has to deal with healthcare...

Republicans have proposed to repeal the Affordable Care Act, colloquially known as "Obamacare," and are seeking approval for the new GOP healthcare bill dubbed Trumpcare. President Donald Trump has proposed significant tax cuts to reduce healthcare expense, with Medicaid expected to bear most of...

Leerink's Global Healthcare Conference kicked off Wednesday and will continue through Thursday. Here is a summary of what Leerink's analysts are saying about some of the notable companies who presented at on Wednesday. Universal Health Services Universal Health Services, Inc. (NYSE: UHS)'s chief...

The Aetna Inc (NYSE: AET) and Humana Inc (NYSE: HUM) deal hangs in limbo as John Bates, the Federal Judge appointed to oversee the case is yet to give a timeline for the final ruling even after the final hearing is over. The deadline, which has been pushed forward twice, now looms large, with...

We are closing in on Donald Trump's elevation to the highest office in the country, and a range of emotions runs through the minds of different stakeholders as Trump has threatened large-scale policy overhauls. One of policies that Trump is taking potshots at is Patient Protection and Affordable...

With the Republicans in control of Capitol Hill, the outlook for Social Security in its current iteration is uncertain as many party members argue for sweeping reforms to Social Security to reduce government spending. Add to that the unreliability of President-elect Donald Trump's rhetoric...

Gilead Sciences, Inc. (NASDAQ: GILD) recently reported a Q3 EPS miss, driven by lower than expected sales of its hepatitis C drugs Harvoni and Sovaldi. The poor performance may have been in response to increasing competition from companies like AbbVie Inc (NYSE: ABBV) and Merck & Co., Inc. (...